Cancers & treatments·Regimen libraryLater line

Everolimus

Checked 2026-09-09

Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy

One cycle

every 28 days

28-day cycle, until progressionOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Everolimus Small-molecule mTOR inhibitor	10 mg once daily	Oral	D1-28

Cycles

until progression

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

Stomatitis is reduced by dexamethasone mouthwash prophylaxis (SWISH).

Used in

Neuroendocrine tumours Renal cell carcinoma HR-positive / HER2-negative breast cancer

Trials

RADIANT-3 and RADIANT-4

Products

Everolimus

Source

RADIANT-4, Lancet 2016

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.